Geldof A A, Slotman B J
Department of Endocrinology/Urology, Free University Hospital, Amsterdam, The Netherlands.
Cancer Lett. 1996 Mar 29;101(2):233-9. doi: 10.1016/0304-3835(96)04140-7.
The radiosensitizing effect of platinum compounds has been demonstrated in a number of tumors. In prostate cancer, clinical and preclinical data concerning an eventual efficacy of the concept of radiosensitization are lacking. In the present study cisplatin and carboplatin have been used as a model to explore radiosensitization in in vitro prostate cancer cell lines. Human (DU-145) and rat (R3327-MATLyLu) prostate tumor cells were irradiated with doses ranging from 0 to 8 Gy in the presence of various concentrations of either cisplatin or carboplatin. For the evaluation of the combined effect of the two treatment modalities, a simple model is presented. Supra-additive treatment effects of combinations of platinum drugs with radiotherapy, both at clinically achievable doses, were shown on the basis of surviving fractions of tumor cells and proved to be significant. These data strongly suggest that radiotherapy may be effectively combined with radiosensitizers such as platinum drugs in prostate cancer therapy, to yield synergism in treatment efficacy.
铂类化合物的放射增敏作用已在多种肿瘤中得到证实。在前列腺癌中，关于放射增敏概念最终疗效的临床和临床前数据尚缺。在本研究中，顺铂和卡铂被用作模型，以探索体外前列腺癌细胞系中的放射增敏作用。在存在不同浓度顺铂或卡铂的情况下，对人（DU-145）和大鼠（R3327-MATLyLu）前列腺肿瘤细胞进行0至8 Gy剂量的照射。为评估这两种治疗方式的联合效果，提出了一个简单模型。基于肿瘤细胞的存活分数显示，铂类药物与放疗联合使用在临床可达到的剂量下均有超相加治疗效果，且被证明具有显著性。这些数据强烈表明，在前列腺癌治疗中，放疗可有效地与放射增敏剂如铂类药物联合使用，以产生治疗效果的协同作用。
